Humira licensed for paediatric Crohn's

The licensed indications for Humira (adalimumab) have been extended to include treatment of severe active Crohn's disease in children aged 6 years and older.

In addition to its Crohn's indication (pictured), Humira is also licensed for ulcerative colitis  | SCIENCE PHOTO LIBRARY
In addition to its Crohn's indication (pictured), Humira is also licensed for ulcerative colitis | SCIENCE PHOTO LIBRARY

Humira (adalimumab) can be prescribed in children who have had an inadequate response to conventional therapy including primary nutrition therapy, a corticosteroid and an immunomodulator, or who are intolerant to or have contraindications for such therapies.

Dosing recommendations

Children weighing less than 40kg should receive an initial dose of 40mg followed by a 20mg dose two weeks later. Dosing should then be continued at 20mg on alternate weeks, increasing to 20mg once weekly if necessary. In children weighing 40kg or more the recommended dose is 80mg initially followed by 40mg two weeks later, then 40mg every one or two weeks. Humira is given by subcutaneous injection.

View Humira record

Further information: AbbVie Ltd

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more